Group items tagged

The General Pharmaceutical Council (GPhC) temporary register which was expected to close on 30 September 2022 will continue for the next two years following a request from the secretary of state for health and social care. The temporary register was set up in 2020 after the then secretary of state asked the GPhC to use its emergency powers in order to rapidly register pharmacy professionals to assist in the national response to the Covid-19 emergency. The UK government has made this decision, which is referenced in its new 'Plan for Patients' in England to enable health professionals on the temporary registers to continue to support the health and social care system. The Government had previously announced that the temporary registers established by the health professional regulators were expected to close on 30 September 2022. The decision by the UK government to ask the regulators to keep the temporary registers means that pharmacy professionals on GPhC temporary register can continue to practise.

Community pharmacies in England will continue to receive the free protective equipment (PPE) as the Government's scheme has been extended for another year until March 2024. The Department of Health and Social Care (DHSC) has announced that it will continue to supply all categories of PPE, free of charge, for frontline health and social care staff according to demand until the end of March 2024, or when stocks run out. Last year, DHSC implemented a new and improved portal platform for eligible providers to access free COVID-19 related PPE supplies. The Pharmaceutical Services Negotiating Commitee (PSNC) said: "Community pharmacy teams can continue to order PPE from the NHS PPE portal for free for as long as stock is available."

The Royal Pharmaceutical Society (RPS) has decided to lease two floors of its east London headquarters to Ingeus, a business with services in employment, health, justice and youth. RPS will retain three floors of the building, including its museum and library on the ground floor, as well as the two upper floors which will be used for events, collaborative working and team meetings. The decision follows an announcement in April that the the Society was re-evaluating whether it needed to hold on to its current office space as homeworking was becoming the norm due to the Covid-19 pandemic. The Society also wanted to maximise value from its property and generate additional revenue which could "be reinvested into further developing our valued products and services". Ingeus runs the government-sponsored Restart Scheme to help people find jobs in their local area.

The Galien Foundation recently announced the winners of the 2024 Prix Galien UK Awards, with the University of Oxford receiving accolades for its groundbreaking contributions to public sector innovation through the PRINCIPLE and PANORAMIC Trials. These trials, spearheaded by Oxford's team of experts, have set a new standard for scientific innovation aimed at improving global health outcomes. Led by University of Oxford, the PRINCIPLE and PANORAMIC Trials epitomize a remarkable collaboration aimed at combating the COVID-19 pandemic.

Walgreens Boots Alliance has announced the launch of its new clinical trials business that aims to use patient data from its pharmacies to help drive up recruitment in studies conducted by drugmakers. With patient recruitment and enrollment remain key challenges in clinical trials, further exacerbated by the COVID-19 pandemic, the company said it can proactively match diverse patient populations to trials across a range of disease areas based on race, gender, socioeconomic status and location with its patient reach and access to an extensive foundation of pharmacy and patient-authorised clinical data. The Boots owner also believes that by leveraging a tech-enabled approach to patient identification and creating a large registry of clinical trial participants, the company will be able to reduce the time it takes to match eligible patients to clinical trials. "Walgreens trusted community presence across the nation, combined with our enterprise-wide data and health capabilities, enables us to pioneer a comprehensive solution that makes health options, including clinical trials, more accessible, convenient and equitable," said Ramita Tandon, chief clinical trials officer, Walgreens.

A new legislation has been introduced to allow authorised pharmacists along with other healthcare professionals in Northern Ireland to certify 'fit notes', health minister Robin Swann has announced. Pharmacists and some other healthcare professionals in England, Scotland and Wales are already allowed to sign 'fit notes'. Swann announced that 'fit notes' were also set to go fully digital in the future, meaning they would no longer need to be signed in ink. He said: "I am delighted to introduce this legislation in Northern Ireland. This change will make it easier for people and employers to get the advice they need so people can stay in work and will help free up doctors' time. "Too often we see people being faced with unnecessary challenges to get a fit note. More professionals being able to offer this vital service will speed up the process and support people to return to or remain in work."

After the government announced to award pay rise to pubic sector workers, pharmacy trade bodies have expressed their disappointment at the neglect shown towards funding crisis in community pharmacy. The National Pharmacy Association (NPA) chair, Andrew Lane, said: "Our sector can't help but feel utterly neglected after seven years of crushing real terms cuts to pharmacy funding, amounting to half a billion pounds, and no hint of any relief to come. "This week's public sector pay awards, which include a large number of our health service colleagues, highlight that there's an unresolved funding crisis in community pharmacy which needs urgent attention." "Four months into this financial year, there is as yet no clarity even on current arrangements." "After stepping up to tackle Covid and keep the wheels on the NHS, the sector deserves better than to be neglected in this way," Andrew opines.

Pfizer said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceuticals, making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs. The boards of both companies have approved the deal, they said. Biohaven shares jumped 70 per cent to $141.31, while Pfizer was up slightly at $48.83. Pfizer is flush with cash from a once-in-a-lifetime surge in revenue from Covid-19 vaccines and therapeutics and has said it is looking to buy companies or drugs that could add at least $25 billion in annual sales by the end of the decade. "The CGRP oral medications, though still somewhat newer entrants in a deeply entrenched space, continue to make steady inroads in disrupting the broader migraine market in the U.S.," said BioHaven chief executive Vlad Coric. Biohaven forecast Nurtec sales of $825 million to $900 million in 2022. Pfizer said it expects the pills to eventually overtake the shots.

Reacting to recommendations from a UK-first independent review, the Department of Health and Social Care (DHSC) has outlined action to tackle potential bias in the design and use of medical devices. Professor Dame Margaret Whitehead, professor of public health at the University of Liverpool, was appointed to lead the review, which focused on three areas - optical devices such as pulse oximeters, AI-enabled devices, and polygenic risk scores (PRS) in genomics. The DHSC commissioned the medical devices review after concerns were raised that pulse oximeters - widely used during the COVID-19 pandemic to monitor blood oxygen levels - were not as accurate for patients with darker skin tones. There were worries that this could cause delays in treatment if dangerously low oxygen levels in such patients were missed. However, no evidence was found from NHS studies indicating that this differing performance had an impact on patient care. Accepting the report's conclusions, the DHSC has committed to several actions, such as ensuring the safe use of pulse oximeter devices across a range of skin tones within the NHS and eliminating racial bias from data sets employed in clinical studies.